Cytokinetics said its Phase 3 ACACIA trial hit twin efficacy goals in symptomatic, non-obstructive hypertrophic cardiomyopathy, with Myqorzo (aficamten) improving both patient-reported symptom scores and cardiovascular fitness versus placebo. The results position the company to expand treatment eligibility beyond obstructive HCM, where the drug already has regulatory traction. The company reported statistically significant improvements from baseline to Week 36 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and maximal exercise performance, using an allosteric, reversible inhibitor of cardiac myosin motor activity. The outcome also builds on Cytokinetics’ earlier obstructive HCM approval. Analysts noted the competitive and commercial significance: an expanded indication could increase the addressable market while differentiating against Bristol Myers Squibb’s rival program, which had previously been separated by disease form. Regulatory review remains the next gate, but the clinical signal is strong enough to reshape near-term payer and clinical adoption expectations for Myqorzo across HCM subtypes.